Aditxt says unit Pearsanta submitted bid to acquire all of Lucira Health assets

Aditxt is pleased to provide an important update regarding its three innovation programs and strategic M&A initiatives. On April 3 Aditxt subsidiary, Pearsanta submitted a bid to acquire substantially all of Lucira Health (LHDXQ) assets, which included Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. At the bankruptcy auction, which was held on April 6 Pearsanta was chosen as the backup bidder. On April 11 , Aditxt filed an objection to the sale of the assets of Lucira to the winning bidder, raising issues as to the fairness and the good faith of Lucira, as well as questioning value maximization for creditors. However, Pearsanta was ultimately designated as the backup bidder. Takeaway: "The interest in the Lucira assets at auction shows the sheer value of the test-to-treat model," said Amro Albanna, co-founder, chairman and CEO of Aditxt and current acting CEO of Pearsanta. "Adixt’s mission is to advance innovations that allow people to make better, smarter, more informed decisions about their health based on more insightful data. The technology that we’ve already invested in-along with the therapeutics in our portfolio-mirror our mission of innovation